Surgerii Robotics, a leading innovator in surgical technology, recently announced the successful closure of a $100 million Series D funding round. Based in Beijing, the company aims to leverage this capital to promote its SHURUI single-port surgical robot both in China and on the international stage, while also accelerating the development of its next-generation products.
Advancements in Single-Port Surgery
Single-port surgery represents a major shift towards minimally invasive techniques, allowing surgeons to operate through a single incision with the assistance of endoscopes and specialized instruments. The SHURUI robot stands out due to its unique use of snake-like instruments and teleoperation technology, facilitating enhanced precision during surgical procedures.
With advancements in laparoscopic surgical robotics, Surgerii has made significant strides in its offerings. The company proudly notes that in September 2025, it received CE approval for the SHURUI system in Europe. This milestone marks Surgerii as the second company to achieve such a certification, following Intuitive Surgical’s recognition for its da Vinci SP system in 2024.
Groundbreaking Technology and Intellectual Property
The SHURUI single-port endoscopic surgical system, designated as the SR-ENS-600, has been heralded as “the world’s first commercially available single-port surgical robot featuring snake-like instruments.” Surgerii has worked diligently to build an extensive intellectual property portfolio, ensuring a competitive edge in the marketplace.
At the heart of the SHURUI SP robot is the innovative “Dual Continuum Mechanism,” developed by Professor Kai Xu from Shanghai Jiao Tong University. This technology enables the creation of flexible instruments capable of performing intricate surgical tasks through a mere 1.8 cm (0.7 in.) incision, showcasing the potential for reduced patient trauma and quicker recovery times.
Navigating a Competitive Landscape
During the funding process, investors conducted thorough evaluations of Surgerii’s intellectual property, analyzing the global technological and patent landscape. This involved a comparative assessment of the SHURUI SP against over 3,000 valid patents held by dominant players in the endoscopic surgical robot sector across Europe and the United States.
The findings indicated that, despite a crowded patent environment, Surgerii’s innovations represent significant breakthroughs. The company asserts that its technologies are distinct from existing surgical patents, establishing a robust foundation for the commercialization and global operation of the SHURUI system.
Regulatory Approvals and Market Reach
The SR-ENS-600 secured marketing approval from China’s National Medical Products Administration (NMPA) in June 2023, marking a historic moment as the first single-port endoscopic surgical robot to gain such certification in China.
In August 2025, the robot obtained CE certification, allowing its deployment in urology, gynecology, general surgery, and thoracic surgery for both adult and pediatric patients. Surgerii emphasizes that it is the sole CE-certified single-port surgical robot authorized for pediatric use and the first Chinese surgical robot to be recognized for use across all age groups.
To date, Surgerii has forged collaborations with over 70 Grade A tertiary hospitals in China, successfully completing more than 3,000 surgeries and participating in nearly 50 procedures globally. The company has also developed over 80 surgical techniques, addressing clinical needs across Asia, including complex surgeries for pancreatic cancer and procedures for infants as young as seven days old.
Commitment to Reduced Surgical Impact
Surgerii Robotics asserts that its technology not only minimizes surgical trauma but also caters to a diverse patient demographic, surpassing the capabilities of traditional multi-port surgical robots. While the SHURUI system has yet to receive approval from the U.S. Food and Drug Administration, its international certifications position it as a formidable player in the surgical robotics market.
Strategic Investment and Future Prospects
Loyal Valley Capital, a prominent private equity firm focused on healthcare and technology advancements, led the Series D funding round. Other notable participants included Shanghai Healthcare Capital, V Star Capital, DNV Capital, and Hefei Industrial Investment, all of which bring extensive experience in healthcare innovations and industrial resources.
Surgerii Robotics views this investment as a pivotal opportunity to deepen its domestic market presence and accelerate its international commercialization efforts. The company intends to enhance clinical adoption and develop advanced energy instruments, enriching the therapeutic capabilities of single-port robots for more complex cases.
A Focus on European Markets
In 2025, Surgerii established the European Clinical Excellence Center in collaboration with IRCAD, a leading institution in minimally invasive surgical training. This strategic partnership signals the company’s commitment to penetrating the high-end European market, aiming to further innovate and improve surgical practices.
The journey of Surgerii Robotics exemplifies the potential of single-use technology in transforming surgical procedures. As the company navigates the challenges and opportunities ahead, its focus on innovation and patient care remains paramount.
Key Takeaways
- Surgerii Robotics raised $100 million in Series D funding to enhance its SHURUI single-port surgical system’s market presence.
- The SHURUI SP is the first commercially available single-port robot with snake-like instruments, emphasizing minimally invasive surgery.
- Regulatory approvals in China and Europe position Surgerii as a leader in pediatric surgical robotics.
- The company has established partnerships with numerous hospitals and has developed over 80 surgical techniques.
- Future plans include expanding clinical adoption and developing advanced surgical instruments for complex cases.
In conclusion, Surgerii Robotics stands at the forefront of surgical innovation, poised to reshape the landscape of minimally invasive surgery. The successful funding round and strategic partnerships underscore its commitment to advancing healthcare technology while enhancing patient outcomes.
Read more → www.therobotreport.com
